The DOI matches its Crossref record; 76 of the 76 references it cites were found in a registry or an index.
Pharmacology of exenatide (synthetic exendin-4): a potential therapeutic for improved glycemic control of type 2 diabetes
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Matthews, D. R., Hosker, J. P., Rudenski, A. S., Naylor, B. A., Treacher, D. F., & Turner, R. C. (1985) · Diabetologia · doi:10.1007/bf00280883 · Cited by 31,502
Turner, R. C., Fox, C., Matthews, McElroy, H. H., Cull, C. A., Holman, R. R., Neil, P., Hadden, D. R., Wright, D., Manley, E., et al. (1998) · The Lancet · Cited by 8,419
Weyer, C., Bogardus, C., Mott, D. M., & Pratley, R. E. (1999) · Journal of Clinical Investigation · doi:10.1172/jci7231 · Cited by 1,940
U.K. Prospective Diabetes Study Group (1995) · Diabetes · doi:10.2337/diab.44.11.1249 · Cited by 1,923
Zander, M., Madsbad, S., Madsen, J. L., & Holst, J. J. (2002) · The Lancet · doi:10.1016/s0140-6736(02)07952-7 · Cited by 1,297
Xu, G., Stoffers, D. A., Habener, J. F., & Bonner-Weir, S. (1999) · Diabetes · doi:10.2337/diabetes.48.12.2270 · Cited by 1,209
Triggering and amplifying pathways of regulation of insulin secretion by glucose.
Henquin, J. C. (2000) · Diabetes · doi:10.2337/diabetes.49.11.1751 · Cited by 1,201 · cited 1×
“This action of exendin-4 contrasts with the action of nonglucose-dependent insulin secretagogues or hypoglycemic agents, such as sulfonylureas, which predominantly increase insulin secretion independent of prevailing glucose concentrations [50] and thus have a greater potential to induce hypoglycemia [27].”
BackgroundKieffer, T. J., McIntosh, C. H., & Pederson, R. A. (1995) · Endocrinology · doi:10.1210/endo.136.8.7628397 · Cited by 1,124
Eng, J., Kleinman, W. A., Singh, L., Singh, G., & Raufman, J. P. (1992) · Journal of Biological Chemistry · doi:10.1016/s0021-9258(18)42531-8 · Cited by 1,000
Thorens, B. (1992) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.89.18.8641 · Cited by 906
Deacon, C. F., Nauck, M. A., Toft-Nielsen, M., Pridal, L., Willms, B., & Holst, J. J. (1995) · Diabetes · doi:10.2337/diab.44.9.1126 · Cited by 878
Göke, R., Fehmann, H. C., Linn, T., Schmidt, H., Krause, M., Eng, J., & Göke, B. (1993) · Journal of Biological Chemistry · doi:10.1016/s0021-9258(19)36565-2 · Cited by 837
Nauck, M. A., Niedereichholz, U., Ettler, R., Holst, J. J., Ørskov, C., Ritzel, R., & Schmiegel, W. H. (1997) · American Journal of Physiology-Endocrinology and Metabolism · doi:10.1152/ajpendo.1997.273.5.e981 · Cited by 817
Scrocchi, L. A., Brown, T. J., Maclusky, N., Brubaker, P. L., Auerbach, A. B., Joyner, A. L., & Drucker, D. J. (1996) · Nature Medicine · doi:10.1038/nm1196-1254 · Cited by 793
Racial and ethnic differences in glycemic control of adults with type 2 diabetes.
Harris, M. I., Eastman, R. C., Cowie, C. C., Flegal, K. M., & Eberhardt, M. S. (1999) · Diabetes Care · doi:10.2337/diacare.22.3.403 · Cited by 646
Drucker, D. J. (1998) · Diabetes · doi:10.2337/diab.47.2.159 · Cited by 601
Glucagon-like Peptide-1 Receptor Signaling Modulates β Cell Apoptosis
Li, Y., Hansotia, T., Yusta, B., Ris, F., Halban, P. A., & Drucker, D. J. (2003) · Journal of Biological Chemistry · doi:10.1074/jbc.m209423200 · Cited by 589
Stoffers, D. A., Kieffer, T. J., Hussain, M. A., Drucker, D. J., Bonner-Weir, S., Habener, J. F., & Egan, J. M. (2000) · Diabetes · doi:10.2337/diabetes.49.5.741 · Cited by 576
Thorens, B., Porret, A., Bühler, L., Deng, S.-P., Morel, P., & Widmann, C. (1993) · Diabetes · doi:10.2337/diab.42.11.1678 · Cited by 558
Kolterman, O. G., Buse, J. B., Fineman, M. S., Gaines, E., Heintz, S., Bicsak, T. A., Taylor, K., Kim, D., Aisporna, M., Wang, Y., et al. (2003) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2002-021545 · Cited by 552
Association, A. D. (2001) · Diabetes Care · doi:10.2337/diacare.24.4.775 · Cited by 464
Exendin-4 reduces fasting and postprandial glucose and decreases energy intake in healthy volunteers
Edwards, C. M. B., Stanley, S. A., Davis, R., Brynes, A. E., Frost, G. S., Seal, L. J., Ghatei, M. A., & Bloom, S. R. (2001) · American Journal of Physiology-Endocrinology and Metabolism · doi:10.1152/ajpendo.2001.281.1.e155 · Cited by 464
Relationships of Upper Gastrointestinal Motor and Sensory Function With Glycemic Control
Rayner, C. K., Samsom, M., Jones, K. L., & Horowitz, M. (2001) · Diabetes Care · doi:10.2337/diacare.24.2.371 · Cited by 460
Young, A. A., Gedulin, B. R., Bhavsar, S., Bodkin, N., Jodka, C., Hansen, B., & Denaro, M. (1999) · Diabetes · doi:10.2337/diabetes.48.5.1026 · Cited by 440
Self-citationTourrel, C., Bailbé, D., Meile, M.-J., Kergoat, M., & Portha, B. (2001) · Diabetes · doi:10.2337/diabetes.50.7.1562 · Cited by 362
Fineman, M. S., Bicsak, T. A., Shen, L. Z., Taylor, K., Gaines, E., Varns, A., Kim, D., & Baron, A. D. (2003) · Diabetes Care · doi:10.2337/diacare.26.8.2370 · Cited by 353
Edwards, C. M., Todd, J. F., Mahmoudi, M., Wang, Z., Wang, R. M., Ghatei, M. A., & Bloom, S. R. (1999) · Diabetes · doi:10.2337/diabetes.48.1.86 · Cited by 344 · cited 1×
“Basedonstudiesusing GLP-1Rknockout (GLP-1R / ) mice and in vitro receptor blockade in islets from these mice, a GLP-1 receptor appears to be involved in, and necessary for, the incretin/insulinotropic actions of exenatide and GLP1, and the hepatic portal glucose sensor actions of GLP-1 [3,35–38].”
BackgroundREAVEN, G. M., CHEN, Y.-D. I., GOLAY, A., SWISLOCKI, A. L. M., & JASPAN, J. B. (1987) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jcem-64-1-106 · Cited by 326
Zhou, J., Wang, X., Pineyro, M. A., & Egan, J. M. (1999) · Diabetes · doi:10.2337/diabetes.48.12.2358 · Cited by 319
Glucagon-like peptide-1 treatment delays the onset of diabetes in 8 week-old db/db mice
Wang, Q., & Brubaker, P. (2002) · Diabetologia · doi:10.1007/s00125-002-0828-3 · Cited by 312
Abraham, E. J. (2002) · Endocrinology · doi:10.1210/en.143.8.3152 · Cited by 310
Baron, A. D., Schaeffer, L., Shragg, P., & Kolterman, O. G. (1987) · Diabetes · doi:10.2337/diab.36.3.274 · Cited by 308
Exendin-4 Decelerates Food Intake, Weight Gain, and Fat Deposition in Zucker Rats
Szayna, M. (2000) · Endocrinology · doi:10.1210/en.141.6.1936 · Cited by 303
Tourrel, C., Bailbe, D., Lacorne, M., Meile, M.-J., Kergoat, M., & Portha, B. (2002) · Diabetes · doi:10.2337/diabetes.51.5.1443 · Cited by 285
Rolin, B., Larsen, M. O., Gotfredsen, C. F., Deacon, C. F., Carr, R. D., Wilken, M., & Knudsen, L. B. (2002) · American Journal of Physiology-Endocrinology and Metabolism · doi:10.1152/ajpendo.00030.2002 · Cited by 281
Neonatal Exendin-4 Prevents the Development of Diabetes in the Intrauterine Growth Retarded Rat
Stoffers, D. A., Desai, B. M., DeLeon, D. D., & Simmons, R. A. (2003) · Diabetes · doi:10.2337/diabetes.52.3.734 · Cited by 261
Egan, J. M. (2002) · Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.87.3.1282 · Cited by 256
Burcelin, R., Da Costa, A., Drucker, D., & Thorens, B. (2001) · Diabetes · doi:10.2337/diabetes.50.8.1720 · Cited by 250
Insulinotropic actions of exendin-4 and glucagon-like peptide-1 in vivo and in vitro
Parkes, D. G., Pittner, R., Jodka, C., Smith, P., & Young, A. (2001) · Metabolism · doi:10.1053/meta.2001.22519 · Cited by 241
Self-citationType 2 Diabetes Mellitus: Update on Diagnosis, Pathophysiology, and Treatment
Mahler, R. J. (1999) · Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.84.4.1165 · Cited by 202
Brubaker, P. L., & Drucker, D. J. (2002) · Receptors and Channels · doi:10.1080/10606820213687 · Cited by 198
Greig, N. H., Holloway, H. W., De Ore, K. A., Jani, D., Wang, Y., Zhou, J., Garant, M. J., & Egan, J. M. (1999) · Diabetologia · doi:10.1007/s001250051111 · Cited by 189
In-vitro differentiation of pancreatic β-cells
Soria, B. (2001) · Differentiation · doi:10.1046/j.1432-0436.2001.680408.x · Cited by 177
Role of Endogenous Glucagon-Like Peptide-1 in Islet Regeneration After Partial Pancreatectomy
De León, D. D., Deng, S., Madani, R., Ahima, R. S., Drucker, D. J., & Stoffers, D. A. (2003) · Diabetes · doi:10.2337/diabetes.52.2.365 · Cited by 172
Therapy of type 2 diabetes mellitus based on the actions of glucagon‐like peptide‐1
Holst, J. J. (2002) · Diabetes/Metabolism Research and Reviews · doi:10.1002/dmrr.328 · Cited by 169
Pederson, R. A., Satkunarajah, M., McIntosh, C. H., Scrocchi, L. A., Flamez, D., Schuit, F., Drucker, D. J., & Wheeler, M. B. (1998) · Diabetes · doi:10.2337/diabetes.47.7.1046 · Cited by 167
Chen, Y. E., & Drucker, D. J. (1997) · Journal of Biological Chemistry · doi:10.1074/jbc.272.7.4108 · Cited by 166
Pharmacokinetic actions of exendin‐4 in the rat: Comparison with glucagon‐like peptide‐1
Parkes, D., Jodka, C., Smith, P., Nayak, S., Rinehart, L., Gingerich, R., Chen, K., & Young, A. (2001) · Drug Development Research · doi:10.1002/ddr.1195 · Cited by 158
Self-citationRaufman, J., Singh, L., Singh, G., & Eng, J. (1992) · Journal of Biological Chemistry · doi:10.1016/s0021-9258(19)36628-1 · Cited by 136
MacLusky, N. J., Cook, S., Scrocchi, L., Shin, J., Kim, J., Vaccarino, F., Asa, S. L., & Drucker, D. J. (2000) · Endocrinology · doi:10.1210/endo.141.2.7326 · Cited by 133
Scrocchi, L. A., Marshall, B. A., Cook, S., Brubaker, P. L., & Drucker, D. J. (1998) · Diabetes · doi:10.2337/diabetes.47.4.632 · Cited by 125
Nishizawa, M., Nakabayashi, H., Kawai, K., Ito, T., Kawakami, S., Nakagawa, A., Niijima, A., & Uchida, K. (2000) · Journal of the Autonomic Nervous System · doi:10.1016/s0165-1838(99)00086-7 · Cited by 117
Vella, A. V., Shah, P. J., Reed, A. S., Adkins, A., Basu, R., & Rizza, R. A. (2003) · Diabetologia · doi:10.1007/s00125-002-0924-4 · Cited by 96
IDRIS, I. R., Patiag, D., Gray, S., & Donnelly, R. (2002) · Biochemical Pharmacology · doi:10.1016/s0006-2952(01)00924-8 · Cited by 95
Caputo, S., Pitocco, D., Ruotolo, V., & Ghirlanda, G. (2001) · Diabetes Care · doi:10.2337/diacare.24.11.2011 · Cited by 86
Bioactive peptides from lizard venoms
Raufman, J. (1996) · Regulatory Peptides · doi:10.1016/0167-0115(96)00135-8 · Cited by 85
Ribel, U., Larsen, M. O., Rolin, B., Carr, R. D., Wilken, M., Sturis, J., Westergaard, L., Deacon, C. F., & Knudsen, L. B. (2002) · European Journal of Pharmacology · doi:10.1016/s0014-2999(02)02189-1 · Cited by 84
Effects of 1-mo bolus subcutaneous administration of exendin-4 in type 2 diabetes
Egan, J. M., Meneilly, G. S., & Elahi, D. (2003) · American Journal of Physiology-Endocrinology and Metabolism · doi:10.1152/ajpendo.00315.2002 · Cited by 83
Pharmacology of exenatide (synthetic exendin-4) for the treatment of type 2 diabetes.
Nielsen, L. L., & Baron, A. (2003) · PubMed · Cited by 82
Self-citationIntra-islet regulation of hormone secretion by glucagon-like peptide-1-(7--36) amide
Heller, R. S., & Aponte, G. W. (1995) · American Journal of Physiology-Gastrointestinal and Liver Physiology · doi:10.1152/ajpgi.1995.269.6.g852 · Cited by 76
Effect of intraportal glucagon-like peptide-1 on glucose metabolism in conscious dogs
Nishizawa, M., Moore, M. C., Shiota, M., Gustavson, S. M., Snead, W. L., Neal, D. W., & Cherrington, A. D. (2003) · American Journal of Physiology-Endocrinology and Metabolism · doi:10.1152/ajpendo.00503.2002 · Cited by 70
Raufman, J., Singh, L., & Eng, J. (1991) · Journal of Biological Chemistry · doi:10.1016/s0021-9258(18)49932-2 · Cited by 65
Baggio, L. L., Adatia, F. A., Bock, T. G., Brubaker, P. L., & Drucker, D. J. (2000) · Journal of Biological Chemistry · doi:10.1074/jbc.m005119200 · Cited by 46
Comparison of the effect of GIP and GLP‐1 (7–36amide) on insulin release from rat pancreatic islets
Siegel, E. G., Schulze, A., Schmidt, W. E., & Creutzfeldt, W. (1992) · European Journal of Clinical Investigation · doi:10.1111/j.1365-2362.1992.tb01820.x · Cited by 40
Dupré, J., Behme, M. T., HRAMIAK, I. M., & Mcdonald, T. J. (1997) · Diabetes Care · doi:10.2337/diacare.20.3.381 · Cited by 39
Vella, A., Shah, P., Reed, A. S., Adkins, A., Basu, R., & Rizza, R. A. (2003) · Diabetologia · doi:10.1007/s00125-003-1250-1 · Cited by 36
Green, G. M., Guan, D., Schwartz, J. G., & Phillips, W. T. (1997) · Diabetologia · doi:10.1007/s001250050654 · Cited by 34
MacLusky, N. J. (2000) · Endocrinology · doi:10.1210/en.141.2.752 · Cited by 34
Fehmann, H. C., Bode, H., Ebert, T., Karl, A., & Göke, B. (1997) · Hormone and Metabolic Research · doi:10.1055/s-2007-979103 · Cited by 32
Influence of glucagon-like peptide-1 on β cell responsiveness
Zawalich, W. S., Zawalich, K. C., & Rasmussen, H. (1993) · Regulatory Peptides · doi:10.1016/0167-0115(93)90137-w · Cited by 31
Insulin Resistance and Insulin Resistance Syndrome
(2013) · CRC Press eBooks · doi:10.3109/9780203217412 · Cited by 26
Regulation of net hepatic glucose uptake: interaction of neural and pancreatic mechanisms
Moore, M., & Cherrington, A. (1996) · annales de biologie animale biochimie biophysique · doi:10.1051/rnd:19960406 · Cited by 18
Modulation of gastric emptying as a therapeutic approach to glycaemic control.
Moyses, C., Young, A., & Kolterman, O. (1996) · PubMed · Cited by 14
Self-citationPathophysiology of type II diabetes mellitus
Pierre-Jerome, C. (2024) · Elsevier eBooks · doi:10.1016/b978-0-443-13328-2.00003-9 · Cited by 11
Cited by
Drucker, D. J., & Nauck, M. A. (2006) · The Lancet · doi:10.1016/s0140-6736(06)69705-5 · Cited by 3,896
Trends in peptide drug discovery
Muttenthaler, M., King, G. F., Adams, D. J., & Alewood, P. F. (2021) · Nature Reviews Drug Discovery · doi:10.1038/s41573-020-00135-8 · Cited by 1,964
DeFronzo, R. A., Ratner, R. E., Han, J., Kim, D. D., Fineman, M. S., & Baron, A. D. (2005) · Diabetes Care · doi:10.2337/diacare.28.5.1092 · Cited by 1,559
Buse, J. B., Henry, R. R., Han, J., Kim, D. D., Fineman, M. S., Baron, A. D., & for the Exenatide-113 Clinical Study Group (2004) · Diabetes Care · doi:10.2337/diacare.27.11.2628 · Cited by 1,346
GLP-1 receptor agonists for individualized treatment of type 2 diabetes mellitus
Meier, J. J. (2012) · Nature Reviews Endocrinology · doi:10.1038/nrendo.2012.140 · Cited by 1,311
Metadata
- Authors
- Nielsen, L. L., Young, A. A., & Parkes, D. G.
- Venue
- Regulatory Peptides
- Publisher
- Elsevier BV
- Published
- 2004-02
- Volume
- 117
- Issue
- 2
- Pages
- 77-88
- ISSN
- 0167-0115 (ISSN-L)
- OpenAlex
- W2167984392
- Cited by
- 457
- References
- 76
- FWCI
- 13.89
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.